Tel Aviv - Delayed Quote ILA

Dna Group (T.R.) Ltd (DNA.TA)

96.10
-2.10
(-2.14%)
At close: 5:24:14 PM GMT+3
Loading Chart for DNA.TA
  • Previous Close 98.20
  • Open 98.20
  • Bid 96.40 x 541600
  • Ask 94.00 x 566500
  • Day's Range 93.40 - 98.10
  • 52 Week Range 59.00 - 118.90
  • Volume 37,475
  • Avg. Volume 266,698
  • Market Cap (intraday) 119.204M
  • Beta (5Y Monthly) -0.19
  • PE Ratio (TTM) 5.34
  • EPS (TTM) 0.18
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children. The company offers its products for use by skilled physicians, nurses, and operators in hospitals and clinics, as well as in pharmacies and other places. In addition, it engages in the development of oral drugs. The company was formerly known as D.N.A Biomedical Solutions Ltd. and changed its name to Dna Group (T.R.) Ltd in November 2022. Dna Group (T.R.) Ltd was incorporated in 2004 and is based in Tel Aviv-Yafo, Israel.

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: DNA.TA

View More

Performance Overview: DNA.TA

Trailing total returns as of 6/9/2025, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .

YTD Return

DNA.TA
5.84%
TA-125 (^TA125.TA)
13.17%

1-Year Return

DNA.TA
18.35%
TA-125 (^TA125.TA)
40.76%

3-Year Return

DNA.TA
23.73%
TA-125 (^TA125.TA)
41.62%

5-Year Return

DNA.TA
50.39%
TA-125 (^TA125.TA)
90.92%

Compare To: DNA.TA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DNA.TA

View More

Valuation Measures

Annual
As of 6/8/2025
  • Market Cap

    120.95M

  • Enterprise Value

    52.64M

  • Trailing P/E

    5.49

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    395.35

  • Price/Book (mrq)

    1.19

  • Enterprise Value/Revenue

    172.01

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7,220.92%

  • Return on Assets (ttm)

    -1.02%

  • Return on Equity (ttm)

    24.46%

  • Revenue (ttm)

    306k

  • Net Income Avi to Common (ttm)

    22.1M

  • Diluted EPS (ttm)

    0.18

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    68.31M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -205.75k

Research Analysis: DNA.TA

View More

Company Insights: DNA.TA

Research Reports: DNA.TA

View More

People Also Watch